Dashboard
Manage Tickers

JAZZ


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

wells-fargo-maintains-overweight-on-jazz-pharmaceuticals-raises-price-target-to-235
Wells Fargo Maintains Overweight on Jazz P...
11/18/2025 19:21:12

Wells Fargo analyst Mohit Bansal maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target ...

baird-maintains-outperform-on-jazz-pharmaceuticals-raises-price-target-to-209
Baird Maintains Outperform on Jazz Pharmac...
11/18/2025 15:26:03

Baird analyst Joel Beatty maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Outperform and raises the price target from $1...

b-of-a-securities-maintains-buy-on-jazz-pharmaceuticals-raises-price-target-to-247
B of A Securities Maintains Buy on Jazz Ph...
11/18/2025 12:31:37

B of A Securities analyst Jason Gerberry maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target...

jazz-pharmaceuticals-stock-rallies-on-positive-phase-3-trial-results-for-ziihera-in-advanced-gastroesophageal-cancer
Jazz Pharmaceuticals Stock Rallies On Posi...
11/17/2025 19:54:25

Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) shares are popping on Monday following the company's positive results of its Phase 3...

morgan-stanley-maintains-overweight-on-jazz-pharmaceuticals-raises-price-target-to-205
Morgan Stanley Maintains Overweight on Jaz...
11/17/2025 17:37:01

Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price targ...

zymeworks-jazz-pharmaceuticals-stocks-climb-on-robust-gastroesophageal-trial-outcomes-and-upcoming-regulatory-plans
Zymeworks, Jazz Pharmaceuticals Stocks Cli...
11/17/2025 17:09:52

Zymeworks rises after Ziihera shows significant PFS and OS benefits in a Phase 3 trial, supporting plans for regulatory filings...

jazz-pharmaceuticals-sigma-lithium-zymeworks-and-other-big-stocks-moving-higher-on-monday
Jazz Pharmaceuticals, Sigma Lithium, Zymew...
11/17/2025 16:39:23

12-health-care-stocks-moving-in-mondays-pre-market-session
12 Health Care Stocks Moving In Monday's P...
11/17/2025 12:06:42

Core News & Articles
Zymeworks And Partners Report Statisticall...
11/17/2025 11:18:46

Ziihera® plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab a...

Core News & Articles
Jazz Pharmaceuticals Released Topline Resu...
11/17/2025 11:11:06

Ziihera plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab an...

jazz-pharma-to-highlight-both-clinical-and-preclinical-research-evaluating-modeyso-and-new-preclinical-data-featuring-jzp3507-in-cns-tumors-at-2025-sno-annual-meeting
Jazz Pharma To Highlight Both Clinical And...
11/11/2025 12:48:19

Data highlight continued progress in Jazz's brain tumor research and demonstrate the company's commitment to advancing ...

rbc-capital-maintains-outperform-on-jazz-pharmaceuticals-raises-price-target-to-155
RBC Capital Maintains Outperform on Jazz P...
11/06/2025 16:15:44

RBC Capital analyst Leonid Timashev maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Outperform and raises the price targ...

jazz-pharmaceuticals-raises-fy2025-gaap-eps-guidance-from-925-750-to-710-520-vs-776-est
Jazz Pharmaceuticals Raises FY2025 GAAP EP...
11/05/2025 21:18:15

Jazz Pharmaceuticals (NASDAQ:JAZZ) raises FY2025 GAAP EPS guidance from $(9.25)-$(7.50) to $(7.10)-$(5.20) vs $(7.76) analyst e...

jazz-pharmaceuticals-raises-fy2025-adj-eps-guidance-from-480-560-to-765-845-vs-533-est-narrows-fy2025-sales-guidance-from-4150b-4300b-to-4175b-4275b-vs-4221b-est
Jazz Pharmaceuticals Raises FY2025 Adj EPS...
11/05/2025 21:18:04

Jazz Pharmaceuticals (NASDAQ:JAZZ) raises FY2025 Adj EPS guidance from $4.80-$5.60 to $7.65-$8.45 vs $5.33 analyst estimate. Na...

jazz-pharmaceuticals-q3-adj-eps-813-beats-592-estimate-sales-1126b-beat-1109b-estimate
Jazz Pharmaceuticals Q3 Adj. EPS $8.13 Bea...
11/05/2025 21:15:16

Jazz Pharmaceuticals (NASDAQ:JAZZ) reported quarterly earnings of $8.13 per share which beat the analyst consensus estimate of ...

earnings-scheduled-for-november-5-2025
Earnings Scheduled For November 5, 2025
11/05/2025 11:12:12

insights-into-jazz-pharmaceuticalss-upcoming-earnings
Insights into Jazz Pharmaceuticals's Upcom...
11/04/2025 17:01:12

jp-morgan-maintains-overweight-on-jazz-pharmaceuticals-lowers-price-target-to-199
JP Morgan Maintains Overweight on Jazz Pha...
10/27/2025 14:32:55

JP Morgan analyst Jessica Fye maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and lowers the price target fro...

alkermes-strikes-21-billion-avadel-deal-gains-access-to-narcolepsy-drug-lumryz
Alkermes Strikes $2.1 Billion Avadel Deal,...
10/22/2025 19:18:55

Alkermes agrees to acquire Avadel for $2.1 billion, adding the successful Lumryz drug and accelerating entry into sleep medicin...

Core News & Articles
Avadel Pharma Announces Global Settlement ...
10/22/2025 10:34:33

Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, tod...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION